- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Anonymous employee alleged Merck Serono neurology KAMs were pushed to achieve 6 calls/contacts per day. Panel found targets risked inconvenience and Code…
Sanofi was found to have breached a prior PMCPA undertaking after a Nursing Times promotional supplement repeated a very similar “only once-daily…
Complaint alleged Roche instigated a Daily Mirror story promoting off-label Avastin use for brain tumours. Panel found allegations not proven on balance…
Napp admitted concerns about a rep’s conduct. Panel found no breach on alleged false pretence for an appointment, but ruled breaches where…
Public complaint alleged Sanofi failed to disclose clinical trial results for Multaq and Jevtana in line with ABPI/IFPMA requirements. Panel reviewed UK-involvement…
A promotional insert summarising NICE guidance for ezetimibe included a broad claim that 35% of UK CHD patients miss cholesterol targets. The…
Media complaint after Telegraph article. PMCPA ruled Hospira’s Croatia site visit/advisory board was not a genuine advisory board, lacked UK certification and…
Boehringer Ingelheim found 103/~275 hard-copy promotional job bags lacked the required final signatory check that printed items matched the certified electronic version.…
Grünenthal admitted Code breaches after an internal Palexia SR video was uploaded to YouTube by a third party. The Panel ruled public…
Anonymous complaint alleged coercive, industry-funded audits/workshops linked to prescribing. Most allegations not proven, but AstraZeneca was found in breach of Clause 9.1…
At a GP meeting, a Meda rep detailed Dymista without proactively stating it was locally ‘grey listed’. PMCPA found the omission misleading…
Complaint about an online Spiolto COPD ad: missing generic name for Spiriva, unclear comparator device, and missing/outdated PI and references. Panel found…
A rep read an in-call statement implying a CCG-backed commercial agreement meant Symbicort cost wasn’t a barrier. The statement lacked patient-scope limits,…
Complaint about Emerade’s claimed 30‑month shelf-life versus shorter expiry supplied by a pharmacy. Panel found the complainant hadn’t shown the claims were…
Shield’s corporate site contained publicly accessible promotional content for Feraccru and promotional descriptions of unlicensed pipeline products. PMCPA found multiple breaches including…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.